文献速递生殖医学

Kisspeptin受体激动剂MVT-602在健康绝经前女性伴或不伴卵巢刺激中的内分泌特征:两项随机安慰剂对照临床试验结果

Endocrine profile of the kisspeptin receptor agonist MVT-602 in healthy premenopausal women with and without ovarian stimulation: results from 2 randomized, placebo-controlled clinical tricals.
PubMed 文献 · Fertil Steril · 2023-11-03

两项随机安慰剂对照平行组剂量探索试验评估MVT-602在健康绝经前女性卵泡期(1期,n=24)及轻度卵巢刺激后(2a期,n=75)的内分泌特征。MVT-602安全耐受,半衰期1.3-2.2小时,2a期3μg组LH平均最大变化82.4 IU/L,排卵时间3.3-3.9天,5天内排卵率75%-100%。

要点

  • MVT-602在整个剂量范围内安全且耐受良好,消除半衰期1.3-2.2小时
  • 2a期3μg MVT-602后LH平均最大变化82.4 IU/L(24.8小时),>15 IU/L持续33小时
  • 给药后排卵时间:MVT-602 3.3-3.9天,曲普瑞林3.4天,安慰剂5.5天

核心结论

  • MVT-602诱导的LH浓度幅度和持续时间与生理性中期LH峰相似,可能用于医学辅助生殖中诱导卵母细胞成熟和排卵。

研究设计与样本

  • 两项随机、安慰剂对照、平行组、剂量探索试验,在临床试验单位进行。
  • 1期试验纳入18-35岁健康女性24例(无卵巢刺激),2a期试验纳入75例(轻度卵巢刺激)。
  • 1期:单次皮下注射MVT-602 0.3、1.0或3.0μg或安慰剂,每剂量组6例。
  • 2a期:单次皮下注射MVT-602 0.1、0.3、1.0或3.0μg(每剂量组16-17例)、曲普瑞林0.2mg(阳性对照,5例)或安慰剂(5例)。

主要发现

  • 两项试验中MVT-602在整个剂量范围内安全且耐受良好,快速吸收和消除,平均消除半衰期1.3-2.2小时。
  • 2a期LH浓度呈剂量依赖性升高;3μg MVT-602给药后24.8小时观察到LH平均最大变化82.4 IU/L,>15 IU/L持续33小时。
  • 给药后排卵时间:MVT-602 3.3-3.9天,曲普瑞林3.4天,安慰剂5.5天。
  • 给药后5天内排卵率:MVT-602 3μg组100%、1μg组88%、0.3μg组82%、0.1μg组75%,曲普瑞林组100%,安慰剂组60%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Kisspeptin is an essential regulator of hypothalamic gonadotropin-releasing hormone release and is required for physiological ovulation. Native kisspeptin-54 can induce oocyte maturation during in vitro fertilization treatment, including in women who are at high risk of ovarian hyperstimulation syndrome. MVT-602 is a potent kisspeptin receptor agonist with prospective utility to treat anovulatory disorders by triggering oocyte maturation and ovulation during medically assisted reproduction (MAR). Currently, the endocrine profile of MVT-602 during ovarian stimulation is unreported. OBJECTIVE: To determine the endocrine profile of MVT-602 in the follicular phase of healthy premenopausal women (phase-1 trial), and after minimal ovarian stimulation to more closely reflect the endocrine milieu encountered during MAR (phase-2a trial). DESIGN: Two randomized, placebo-controlled, parallel-group, dose-finding trials. SETTING: Clinical trials unit. PATIENTS: Healthy women aged 18-35 years, either without (phase-1; n = 24), or with ovarian stimulation (phase-2a; n = 75). INTERVENTIONS: Phase-1: single subcutaneous dose of MVT-602 (0.3, 1.0, or 3.0 μg) or placebo, (n = 6 per dose). Phase-2a: single subcutaneous dose of MVT-602 (0.1, 0.3, 1.0, or 3.0 μg; n = 16-17 per dose), triptorelin 0.2 mg (n = 5; active comparator), or placebo (n = 5). MAIN OUTCOME MEASURES: Phase-1: safety/tolerability; pharmacokinetics; and pharmacodynamics (luteinizing hormone [LH] and other reproductive hormones). Phase-2a: safety/tolerability; pharmacokinetics; pharmacodynamics (LH and other reproductive hormones); and time to ovulation assessed by transvaginal ultrasound. RESULTS: In both the trials, MVT-602 was safe and well tolerated across the entire dose range. It was rapidly absorbed and eliminated, with a mean elimination half-life of 1.3-2.2 hours. In the phase-2a trial, LH concentrations increased dose dependently; mean maximum change from baseline of 82.4 IU/L at 24.8 hours was observed after administration of 3 μg MVT-602 and remained >15 IU/L for 33 hours. Time to ovulation after drug administration was 3.3-3.9 days (MVT-602), 3.4 days (triptorelin), and 5.5 days (placebo). Ovulation occurred within 5 days of administration in 100% (3 μg), 88% (1 μg), 82% (0.3 μg), and 75% (0.1 μg), of women after MVT-602, 100% after triptorelin and 60% after placebo. CONCLUSIONS: MVT-602 induces LH concentrations of similar amplitude and duration as the physiological midcycle LH surge with potential utility for induction of oocyte maturation and ovulation during MAR. CLINICAL TRIAL REGISTRATION NUMBER: EUDRA-CT: 2017-003812-38, 2018-001379-20.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Abbara A, Ufer M, Voors-Pette C, et al. Endocrine profile of the kisspeptin receptor agonist MVT-602 in healthy premenopausal women with and without ovarian stimulation: results from 2 randomized, placebo-controlled clinical tricals. Fertil Steril. 2023. PMID: 37925096. doi:10.1016/j.fertnstert.2023.10.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。